X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
mutation (9) 9
index medicus (8) 8
humans (7) 7
isocitrate dehydrogenase - genetics (7) 7
isocitrate dehydrogenase (6) 6
differentiation (5) 5
female (5) 5
leukemia (5) 5
leukemia, myeloid, acute - genetics (5) 5
middle aged (5) 5
2-hydroxyglutarate (4) 4
acute myeloid-leukemia (4) 4
adult (4) 4
aged (4) 4
cells (4) 4
inhibitor (4) 4
male (4) 4
myeloid leukemia (4) 4
oncology (4) 4
prognosis (4) 4
abridged index medicus (3) 3
acute myeloid leukemia (3) 3
aged, 80 and over (3) 3
hematology (3) 3
isocitrate dehydrogenase - antagonists & inhibitors (3) 3
leukemia, myeloid, acute - drug therapy (3) 3
leukemia, myeloid, acute - pathology (3) 3
oncometabolite 2-hydroxyglutarate (3) 3
patients (3) 3
pharmacokinetics (3) 3
pharmacology (3) 3
physiological aspects (3) 3
remission induction (3) 3
research (3) 3
sufficient (3) 3
tumors (3) 3
2‐hydroxyglutarate (2) 2
adolescent (2) 2
antineoplastic agents - therapeutic use (2) 2
article (2) 2
cancer (2) 2
cell differentiation (2) 2
cell line, tumor (2) 2
cholangiocarcinoma (2) 2
dehydrogenases (2) 2
drug therapy (2) 2
enzyme inhibitors - adverse effects (2) 2
enzyme inhibitors - pharmacokinetics (2) 2
enzyme inhibitors - pharmacology (2) 2
enzymes (2) 2
erythrocytes (2) 2
evolution (2) 2
eye disease (2) 2
gene mutations (2) 2
glutarates - blood (2) 2
idh1 (2) 2
idh2 mutations (2) 2
impact (2) 2
inhibitors (2) 2
isocitrate dehydrogenase 1 (2) 2
leukemia, myeloid, acute - mortality (2) 2
liquid chromatography (2) 2
mass spectrometry (2) 2
mass spectroscopy (2) 2
metabolites (2) 2
mutant idh2 (2) 2
mutations (2) 2
ophthalmology (2) 2
pharmacodynamics (2) 2
pharmacology & pharmacy (2) 2
phenylurea compounds - pharmacology (2) 2
point mutation (2) 2
prognostic-significance (2) 2
remission (2) 2
sulfonamides - pharmacology (2) 2
urine (2) 2
young adult (2) 2
2 mutations (1) 1
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
absorption (1) 1
adenocarcinoma - blood (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - pathology (1) 1
adenocarcinoma - urine (1) 1
administration, oral (1) 1
allosteric site (1) 1
aminopyridines - adverse effects (1) 1
aminopyridines - pharmacokinetics (1) 1
aminopyridines - therapeutic use (1) 1
analysis (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - chemistry (1) 1
antineoplastic agents - metabolism (1) 1
antineoplastic agents - pharmacokinetics (1) 1
antineoplastic agents - pharmacology (1) 1
apolipoprotein-e (1) 1
arms2 (1) 1
assay (1) 1
association (1) 1
bile duct neoplasms - blood (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science, ISSN 0036-8075, 5/2013, Volume 340, Issue 6132, pp. 622 - 626
A number of human cancers harbor somatic point mutations in the genes encoding isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2). These mutations alter... 
Molecules | Enzymes | Dehydrogenases | Blasts | Myeloid leukemia | REPORTS | Stem cells | Bone marrow cells | Cellular differentiation | Hematopoietic stem cells | Mesenchymal stem cells | ISOCITRATE DEHYDROGENASE | ONCOMETABOLITE 2-HYDROXYGLUTARATE | SUFFICIENT | MULTIDISCIPLINARY SCIENCES | HEMATOPOIETIC PROGENITORS | MUTATION | Cell Proliferation | Humans | Protein Multimerization | Crystallography, X-Ray | Erythropoiesis - drug effects | Isocitrate Dehydrogenase - antagonists & inhibitors | Molecular Targeted Therapy | Hematopoiesis - drug effects | Antineoplastic Agents - metabolism | Leukemia, Myeloid, Acute - enzymology | Phenylurea Compounds - chemistry | Enzyme Inhibitors - chemistry | Leukemia, Myeloid, Acute - drug therapy | Antineoplastic Agents - pharmacology | Phenylurea Compounds - metabolism | Mutant Proteins - antagonists & inhibitors | Catalytic Domain | Enzyme Inhibitors - metabolism | Protein Structure, Secondary | Sulfonamides - chemistry | Leukemia, Myeloid, Acute - pathology | Cells, Cultured | Enzyme Inhibitors - pharmacology | Isocitrate Dehydrogenase - genetics | Mutant Proteins - metabolism | Gene Expression Regulation, Leukemic | Antineoplastic Agents - chemistry | Sulfonamides - pharmacology | Point Mutation | Isocitrate Dehydrogenase - chemistry | Small Molecule Libraries | Mutant Proteins - chemistry | Allosteric Site | Sulfonamides - metabolism | Cell Line, Tumor | Isocitrate Dehydrogenase - metabolism | Glutarates - metabolism | Phenylurea Compounds - pharmacology | Leukemia, Erythroblastic, Acute | Leukemia, Myeloid, Acute - genetics | Leukemia | Cancer cells | Physiological aspects | Research | Oxidoreductases | Cell differentiation | Health aspects | Mutation | Cellular biology | Drug therapy | Cells
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 25, pp. 2386 - 2398
Among patients with IDH1 -mutated relapsed or refractory leukemia, daily oral ivosidenib, an IDH1 inhibitor, induced molecular clearance of leukemic cells from... 
MEDICINE, GENERAL & INTERNAL | IDH2 MUTATIONS | METAANALYSIS | ACUTE MYELOID-LEUKEMIA | PROGNOSTIC-SIGNIFICANCE | DIFFERENTIATION | INHIBITOR | Glycine - analogs & derivatives | Recurrence | Follow-Up Studies | Glycine - adverse effects | Cell Count | Humans | Middle Aged | Pyridines - pharmacokinetics | Drug Resistance, Neoplasm | Male | Isocitrate Dehydrogenase - antagonists & inhibitors | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Young Adult | Pyridines - adverse effects | Enzyme Inhibitors - pharmacokinetics | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Glycine - administration & dosage | Enzyme Inhibitors - adverse effects | Glycine - pharmacokinetics | Pyridines - administration & dosage | Administration, Oral | Isocitrate Dehydrogenase - genetics | Survival Rate | Remission Induction | Leukemia, Myeloid, Acute - mortality | Adolescent | Aged | Mutation | Hemoglobins - analysis | Leukemia, Myeloid, Acute - genetics | Usage | Myelocytic leukemia | Gene mutations | Physiological aspects | Genetic aspects | Nonlymphoid leukemia | Research | Drug therapy | Isocitrate dehydrogenase | Risk factors | Thrombocytopenia | Myeloid leukemia | Leukemia | FDA approval | Cancer therapies | Patients | Investigations | Leukocytosis | Collaboration | Point mutation | Remission | Acute myeloid leukemia | Drug dosages | Neutropenia | Tumors
Journal Article
Blood, ISSN 0006-4971, 08/2017, Volume 130, Issue 6, pp. 722 - 731
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 05/2019, Volume 83, Issue 5, p. 837
Pharmacokinetics, absorption, metabolism, and excretion of ivosidenib, a mutant isocitrate dehydrogenase-1 inhibitor, were determined in healthy male subjects.... 
Metabolites | Analysis | Cytochrome P-450 | Physiological aspects
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 1310 - 1310
Abstract INTRODUCTION: Somatic IDH1/2 mutations occur in multiple solid and hematologic tumors, including acute myeloid leukemia. Mutant IDH1/2 proteins have... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 4548 - 4548
Abstract INTRODUCTION: Pyruvate kinase (PK) deficiency is a congenital hemolytic anemia caused by deficient function of the PK enzyme. This condition is... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 3737 - 3737
Abstract Introduction: Isocitrate dehydrogenase (IDH) is a critical enzyme in the citric acid cycle, catalyzing the oxidative decarboxylation of isocitrate to... 
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 3336 - 3336
Abstract INTRODUCTION: Pyruvate kinase (PK) deficiency is a glycolytic enzymopathy that results in non-spherocytic hemolytic anemia with a variable clinical... 
Journal Article
Journal Article